Kiora Pharmaceuticals (NASDAQ:KPRX) Announces Quarterly Earnings Results, Beats Estimates By $0.73 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) posted its quarterly earnings data on Friday. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.73, Zacks reports.

Kiora Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ KPRX traded up $0.01 during midday trading on Friday, reaching $2.33. 11,622 shares of the stock were exchanged, compared to its average volume of 51,811. Kiora Pharmaceuticals has a 12 month low of $2.21 and a 12 month high of $4.18. The business has a 50-day simple moving average of $2.62 and a two-hundred day simple moving average of $2.85.

Analysts Set New Price Targets

A number of brokerages recently commented on KPRX. Zacks Research lowered Kiora Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Kiora Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Friday, October 31st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kiora Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.